Novel Compounds in the Treatment of the CNS Disorders II

Dear Colleagues,

Central nervous system (CNS) disorders are a broad group of neurological conditions affecting the functioning of the brain or spinal cord, and in consequence, deteriorating the quality of life of a given patient. Amongst them, bipolar disorder, depression, epilepsy/seizures, migraine, Parkinson's disease, Alzheimer's disease, Huntington's disease, attention deficit/hyperactivity disorder, and multiple sclerosis are most frequently diagnosed. These neurological conditions can be caused by several different factors, such as stroke, trauma, infections, autoimmune disorders, tumors, brain or spinal cord degeneration, structural defects, or genetic determinants. Despite the enormous progress in medicine and pharmacotherapy, the management of CNS diseases is still challenging; most of these disorders cannot be thoroughly cured, not all patients achieve even partial remission, and prescribed drugs induce troublesome side effects. Therefore, continuous attempts have been made to develop new treatment strategies and safer, more effective drugs. Research and medical teams focus on diverse treatment options: innovative compounds, combinations of well-known substances, as well as surgical and neurorehabilitation procedures. In our Special Issue on Novel Compounds in the Treatment of the CNS Disorders, we aim to bring together experts working in the field of neurological conditions and invite them to present their recent results from both pre-clinical and clinical studies related to the pharmacotherapy of CNS disorders. Review articles and short communications on the latest achievements in the management of the CNS disorders are also welcome.

Prof. Dr. Ewa Poleszak
Dr. Anna Serefko
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• ADHD
• autism
• depression
• epilepsy
• neurodegenerative diseases
• neuroscience
• preclinical studies
• clinical studies
• anxiety
• schizophrenia

• Novel Compounds in the Treatment of the CNS Disorders in Molecules (12 articles)